These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24917246)

  • 21. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
    Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
    Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
    Krishnaiah M; Jin CH; Sheen YY; Kim DK
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
    Distler O; Cozzio A
    Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring anti-TGF-β therapies in cancer and fibrosis.
    Hawinkels LJ; Ten Dijke P
    Growth Factors; 2011 Aug; 29(4):140-52. PubMed ID: 21718111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis.
    Prakash J; de Borst MH; van Loenen-Weemaes AM; Lacombe M; Opdam F; van Goor H; Meijer DK; Moolenaar F; Poelstra K; Kok RJ
    Pharm Res; 2008 Oct; 25(10):2427-39. PubMed ID: 18183478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
    Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
    J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
    Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
    Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
    Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
    Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor up-regulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblasts.
    Yamane K; Ihn H; Tamaki K
    Arthritis Rheum; 2003 Jun; 48(6):1652-66. PubMed ID: 12794834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors.
    Araujo SC; Maltarollo VG; Almeida MO; Ferreira LLG; Andricopulo AD; Honorio KM
    Molecules; 2020 Jan; 25(2):. PubMed ID: 31936488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gefitinib attenuates transforming growth factor-β1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells.
    Chen SC; Guh JY; Lin TD; Chiou SJ; Hwang CC; Ko YM; Chuang LY
    Transl Res; 2011 Oct; 158(4):214-24. PubMed ID: 21925118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Szokol B; Gyulavári P; Baska F; Ibolya K; Greff Z; Szántai KC; Zoltán O; Peták I; Axel U; Vantus T; Kéri G; Orfi L
    Acta Pharm Hung; 2013; 83(4):121-33. PubMed ID: 24575658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.
    Liang R; Šumová B; Cordazzo C; Mallano T; Zhang Y; Wohlfahrt T; Dees C; Ramming A; Krasowska D; Michalska-Jakubus M; Distler O; Schett G; Šenolt L; Distler JH
    Ann Rheum Dis; 2017 Apr; 76(4):756-764. PubMed ID: 27793816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aggregatibacter actinomycetemcomitans outer membrane protein 29 (Omp29) induces TGF-β-regulated apoptosis signal in human gingival epithelial cells via fibronectin/integrinβ1/FAK cascade.
    Yoshimoto T; Fujita T; Kajiya M; Ouhara K; Matsuda S; Komatsuzawa H; Shiba H; Kurihara H
    Cell Microbiol; 2016 Dec; 18(12):1723-1738. PubMed ID: 27121139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
    Kovacs RJ; Maldonado G; Azaro A; Fernández MS; Romero FL; Sepulveda-Sánchez JM; Corretti M; Carducci M; Dolan M; Gueorguieva I; Cleverly AL; Pillay NS; Baselga J; Lahn MM
    Cardiovasc Toxicol; 2015 Oct; 15(4):309-23. PubMed ID: 25488804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
    Zhu LX; Liu Q; Hua YF; Yang N; Zhang XG; Ding X
    Comput Biol Chem; 2019 Jun; 80():324-332. PubMed ID: 31078911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: A case study on the cancer MAPK signaling pathway.
    Meng L; Huang Z
    Comput Biol Chem; 2018 Aug; 75():196-204. PubMed ID: 29803964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice.
    Liang S; Hu J; Xie Y; Zhou Q; Zhu Y; Yang X
    Int J Nanomedicine; 2016; 11():6753-6762. PubMed ID: 28008250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.
    Pan YL; Liu YL; Chen JZ
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.